Victoria Callahan

Medicine · Health Sciences

10h-index499citations19works2.82yr avg
OpenAlex↗ORCID↗Google Scholar↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Mosquito-borne diseases and control(10), SARS-CoV-2 and COVID-19 Research(8), Viral Infections and Vectors(6), COVID-19 Clinical Research Studies(5), Viral Infections and Outbreaks Research(5)

Publications19 total

High binding potency overcomes the requirement of Fc effector functions for broadly reactive anti-alphavirus antibodies
Science Translational Medicine·2025· 1 citedOpen Access
Requirement for Fc effector function is overcome by binding potency for broadly reactive anti-alphavirus antibodies
2024· 1 citedOpen Access
Recombinant OC43 SARS-CoV-2 spike replacement virus: An improved BSL-2 proxy virus for SARS-CoV-2 neutralization assays
Proceedings of the National Academy of Sciences·2024· 12 citedOpen Access
Single-particle cryo-EM unaligned micrographs of antibody SKT05 in complex with Western Equine Encephalitis Virus-Like Particles
EMPIAR dataset·2024Open Access
Single-particle cryo-EM unaligned micrographs of antibody SKW11 in complex with Western Equine Encephalitis Virus-Like Particles
EMPIAR dataset·2024Open Access
Vaccine elicitation and structural basis for antibody protection against alphaviruses
Cell·2023· 32 citedOpen Access
Bioprospecting the American Alligator Peptidome for antiviral peptides against Venezuelan equine encephalitis virus
PROTEOMICS·2022· 1 cited
Implementation of SARS-CoV-2 Monoclonal Antibody Infusion Sites at Three Medical Centers in the United States: Strengths and Challenges Assessment to Inform COVID-19 Pandemic and Future Public Health Emergency Use
Disaster Medicine and Public Health Preparedness·2022· 8 citedOpen Access
The Pro-Inflammatory Chemokines CXCL9, CXCL10 and CXCL11 Are Upregulated Following SARS-CoV-2 Infection in an AKT-Dependent Manner
Viruses·2021· 141 citedOpen Access
Alpha 1 Antitrypsin is an Inhibitor of the SARS-CoV-2–Priming Protease TMPRSS2
Pathogens and Immunity·2021· 108 citedOpen Access
Implementation of SARS-CoV-2 monoclonal antibody infusion sites at three medical centers in the United States: Strengths and challenges assessment to inform COVID-19 pandemic and future public health emergency use
2021· 5 citedOpen Access
Proteomic Discovery of VEEV E2-Host Partner Interactions Identifies GRP78 Inhibitor HA15 as a Potential Therapeutic for Alphavirus Infections
Pathogens·2021· 15 citedOpen Access
Hydrogel particles improve detection of SARS-CoV-2 RNA from multiple sample types
Scientific Reports·2020· 22 citedOpen Access
Nanotrap <sup>®</sup> particles improve detection of SARS-CoV-2 for pooled sample methods, extraction-free saliva methods, and extraction-free transport medium methods
2020· 4 citedOpen Access
Alpha 1 Antitrypsin is an Inhibitor of the SARS-CoV-2–Priming Protease TMPRSS2
2020· 50 citedOpen Access
Use of Nanotrap particles for the capture and enrichment of Zika, chikungunya and dengue viruses in urine
PLoS ONE·2020· 22 citedOpen Access
A Proteomics Analysis of In Vitro Host-Protein Binding Partners of Western Equine Encephalitis Virus (WEEV) Capsid Protein
2020Open Access
Phloretin inhibits Zika virus infection by interfering with cellular glucose utilisation
International Journal of Antimicrobial Agents·2019· 43 cited
New World alphavirus protein interactomes from a therapeutic perspective
Antiviral Research·2019· 34 cited

Frequent Co-authors

Kylene Kehn‐Hall(10), Ivan Akhrymuk(7), Mario Roederer(5), Caitlin W. Lehman(4), Julie M. Fox(4), Shih‐Chao Lin(3), Aarthi Narayanan(3), Matthew S. Sutton(3), Yaroslav Tsybovsky(3), Ryan G. Casner(3), Gabriele Cerutti(3), Christina L. Gardner(3), Veronica Guirguis(3), Raffaello Verardi(3), David R. Ambrozak(3), Margaret H. Beddall(3), Reda Rawi(3), Arne Schön(3), Wei Shi(3), Yongping Yang(3)